Lista de obras - Mark M Smits - Dominio Público Uruguay

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes

artículo científico publicado en 2016

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2016

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.

artículo científico publicado en 2016

Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis

artículo científico publicado en 2013

Advances in pharmacologic therapies for type 2 diabetes

artículo científico

Arm length is associated with type 2 diabetes mellitus in Japanese-Americans.

artículo científico publicado en 2012

Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance

scientific article published on 26 August 2019

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

artículo científico publicado en 2016

Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes

scientific article published on 01 April 2020

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

artículo científico publicado en 2015

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

scientific article published on 10 August 2014

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

artículo científico publicado en 2015

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.

artículo científico publicado en 2016

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels

artículo científico publicado en 2015

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

artículo científico publicado en 2018

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

artículo científico publicado en 2020

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

artículo científico publicado en 2020

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

artículo científico publicado en 2020

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

artículo científico publicado en 2019

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

artículo científico publicado en 2015

Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial

artículo científico publicado en 2016

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

artículo científico publicado en 2015

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

artículo científico publicado en 2017

GLP-1 based therapies: clinical implications for gastroenterologists.

artículo científico publicado en 2016

GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials

artículo científico publicado en 2019

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

artículo científico publicado en 2016

Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.

artículo científico publicado en 2015

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

artículo científico publicado en 2017

Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial

scientific article published on 13 January 2016

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

artículo científico publicado en 2016

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

artículo científico publicado en 2020

Incretin-based drugs and renoprotection—is hyperfiltration key?

artículo científico publicado en 2015

Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.

artículo científico publicado en 2016

Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes

artículo científico publicado en 2021

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients

artículo científico publicado en 2018

Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups

artículo científico publicado en 2013

Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease

artículo científico publicado en 2010

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

artículo científico publicado en 2016

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

artículo científico publicado en 2017

Plasma uric acid and renal haemodynamics in type 2 diabetes patients

scientific article published on 12 September 2019

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

artículo científico publicado en 2015

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

artículo científico

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

artículo científico publicado en 2016

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

artículo científico publicado en 2019

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

article

Renoprotection in LEADER and EMPA-REG OUTCOME

artículo científico publicado en 2016

Smoking Is Related to Pancreatic Fibrosis in Humans

artículo científico publicado en 2011

Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study

artículo científico publicado en 2017

Soil fungi appear to have a retarding rather than a stimulating role on soil apatite weathering

artículo científico publicado en 2014

The clinical significance of pancreatic steatosis

artículo científico publicado en 2011

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

artículo científico publicado en 2016

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

artículo científico publicado en 2013

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

scientific article published on 10 October 2019

The role of phosphorus, magnesium and potassium availability in soil fungal exploration of mineral nutrient sources in Norway spruce forests

artículo científico publicado en 2016

The soil organic matter decomposition mechanisms in ectomycorrhizal fungi are tuned for liberating soil organic nitrogen

artículo científico publicado en 2018

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

artículo científico publicado en 2016

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

artículo científico publicado en 2014

Understanding EMPA-REG OUTCOME

artículo científico publicado en 2015

Lista de obras de Mark M Smits

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.

Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis

Advances in pharmacologic therapies for type 2 diabetes

Arm length is associated with type 2 diabetes mellitus in Japanese-Americans.

Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance

Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.

Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.

Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.

Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels

Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials

Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial

Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050

Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men.

GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes

GLP-1 based therapies: clinical implications for gastroenterologists.

GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials

GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial

Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial

Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.

High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients

Incretin-based drugs and renoprotection—is hyperfiltration key?

Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database.

Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients

Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups

Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.

Plasma uric acid and renal haemodynamics in type 2 diabetes patients

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Renal sinus fat and renal hemodynamics: a cross-sectional analysis

Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus

Renoprotection in LEADER and EMPA-REG OUTCOME

Smoking Is Related to Pancreatic Fibrosis in Humans

Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study

Soil fungi appear to have a retarding rather than a stimulating role on soil apatite weathering

The clinical significance of pancreatic steatosis

The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

The role of phosphorus, magnesium and potassium availability in soil fungal exploration of mineral nutrient sources in Norway spruce forests

The soil organic matter decomposition mechanisms in ectomycorrhizal fungi are tuned for liberating soil organic nitrogen

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase

Understanding EMPA-REG OUTCOME